Cytovation as
WebMar 21, 2024 · Cytovation ASA is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class immunotherapy targeting the cell membrane of tumor cells. The company is a spin-off from the University of Bergen (Norway), the city where it is headquartered. For more information, please visit …
Cytovation as
Did you know?
WebMar 18, 2024 · BERGEN, NORWAY, 18 March 2024 – Cytovation AS, a privately held biotech company, announces that the first patients have been treated in a Phase I clinical study with CyPep-1, a novel therapeutic agent being developed as a new topical therapy for HPV-induced warts. WebFeb 7, 2024 · CyPep-1 is a chemically synthesized peptide with oncolytic properties. It selectively targets cancer cells based on their altered molecular composition, and removes the surrounding cell membrane. This releases tumor neoantigens to the microenvironment and potentially induces an anti-tumour immune response.
WebSep 15, 2024 · BERGEN, Norway, Sept. 15, 2024 /PRNewswire/ -- Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane... WebAbout Cytovation Cytovation ASA is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class tumor membrane targeting agent. The company is a spin-off from the University of Bergen (Norway), the city where it is headquartered. For more information, please visit www.cytovation.com .
WebFeb 17, 2024 · Cytovation ASA is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class tumorolytic agent targeting the cell membrane of tumor cells. The company is a spin-off from the University of Bergen (Norway), the city where it is headquartered. For more information, please visit … WebCytovation ASA 622 følgere på LinkedIn. TARGETED TUMOR MEMBRANE IMMUNOTHERAPY Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic …
WebNov 15, 2024 · Cytovation AS is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class tumorolytic agent targeting the cell membrane of tumor cells. The...
WebCytovation builds on over 15 years of cutting-edge research. About us. Targeted Tumor Membrane Immunotherapy . By novel peptide engineering, we guide the immune system … Cytovation develops treatments for solid tumors in oncology and rare diseases. A … Norwegian office Solheimsgaten 11 5058 Bergen Norway. … Our approach eliminates cancer cells by forming pores in the plasma membrane, … Stay up to date on ourlatest news and announcements. Cytovation builds on over 15 years of cutting-edge research from two leading … Cytovation ASA is a company registered in Bergen, Norway. Registered number … how to spell orderveWebMar 21, 2024 · Cytovation appoints Iman Barilero as Chief Development Officer - Benzinga Bergen, Norway, 21 March 2024 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of... how to spell orchardWebMar 21, 2024 · Cytovation ASA is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class immunotherapy … how to spell orchestra correctlyWebJan 27, 2024 · Published: Jan 27, 2024 By Alex Keown. Cytovation AS, a clinical-stage oncology company based in Norway, raised $20 million in a Series A financing round. Funds will be used to advance the … how to spell ordnanceWebMar 21, 2024 · Cytovation ASA is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class immunotherapy … how to spell orderWebApr 12, 2024 · Bergen, Norway, 21 March 2024 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer.. Dr. Barilero brings three decades of experience … how to spell orderves rightWebMar 21, 2024 · Cytovation ASA is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class immunotherapy … rds fichier